Page 306 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 15 Molecular/Targeted Therapy of Cancer 285

510. Smith V, Sausville EA, Camalier RF, et al.: Comparison of 515. Kaur G, Belotti D, Burger AM, et al.: Antiangiogenic properties of
17–dimethylaminoethylamino-17–demethoxy-geldanamycin 17–(dimethylaminoethylamino)-17-demethoxygeldanamycin: an
(17DMAG) and 17–allylamino-17–demethoxygeldanamycin orally bioavailable heat shock protein 90 modulator, Clin Cancer
VetBooks.ir (17AAG) in vitro: effects on Hsp90 and client proteins in mela- 516. Hawkins LM, Jayanthan AA, Narendran A: Effects of 17-allyl-
Res 10:4813–4821, 2004.
noma models, Cancer Chemother Pharmacol 56:126–137, 2005.
511. Burger AM, Fiebig HH, Stinson SF, et al.: 17-(Allylamino)-17-de-
methoxygeldanamycin activity in human melanoma models, Anti- amino-17-demethoxygeldanamycin (17-AAG) on pediatric acute
lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and
cancer Drugs 15:377–387, 2004. imatinib mesylate sensitivity, Pediatr Res 57:430–437, 2005.
512. Park JW, Yeh MW, Wong MG, et al.: The heat shock protein 90– 517. Villa R, Folini M, Porta CD, et al.: Inhibition of telomerase
binding geldanamycin inhibits cancer cell proliferation, down-reg- activity by geldanamycin and 17-allylamino, 17-demethox-
ulates oncoproteins, and inhibits epidermal growth factor-induced ygeldanamycin in human melanoma cells, Carcinogenesis 24:
invasion in thyroid cancer cell lines, J Clin Endocrinol Metab 851–859, 2003.
88:3346–3353, 2003. 518. Haendeler J, Hoffmann J, Rahman S, et al.: Regulation of
513. Blagosklonny MV: Hsp-90-associated oncoproteins: multiple tar- telomerase activity and anti-apoptotic function by protein-
gets of geldanamycin and its analogs, Leukemia 16:455–462, 2002. protein interaction and phosphorylation, FEBS Lett 536:
514. Aoyagi Y, Fujita N, Tsuruo T: Stabilization of integrin-linked 180–186, 2003.
kinase by binding to Hsp90, Biochem Biophys Res Commun 331:
1061–1068, 2005.